Información del artículo
El Texto completo está disponible en PDF
Bibliogrífia
[1.]
M.B. Hansen, E. Skadhauge.
Signal transduction pathways for serotonin as an intestinal secretagogue.
Comp Biochem Physiol, 118A (1997), pp. 283-290
[2.]
M. Vialli, V. Erspamer.
Cellule enterocromaffini e cellule basigranulose acidofile nei vertebrati.
Z Zellfrosc Mikrosk Anat, 19 (1933), pp. 743
[3.]
M.M. Rapport, A.A. Green, I.H. Page.
Purification of the substance which is responsible for vasoconstrictor activity of serum.
Fed Proc, 6 (1947), pp. 184
[4.]
M.M. Rapport, A.A. Green, I.H. Page.
Serum vasoconstrictor (serotonin): isolation and characterization.
J Biol Chem, 176 (1948), pp. 1243-1251
[5.]
J.H. Gaddum, Z.P. Picarelli.
Two kinds of tryptamine receptors.
Br J Pharmacol Chemother, 12 (1957), pp. 323-328
[6.]
S.J. Peroutka, S.H. Snyder.
Multiple serotonin receptors: differential binding of (3H)5-HT, (3H)LSD and (3H)spiroperidol.
Mol Pharmacol, 16 (1979), pp. 687-695
[7.]
J.J. Lucas, R. Hen.
New players in the 5-HT receptor field: genes and knockouts.
Trends Pharmacol Sci, 16 (1995), pp. 246-252
[8.]
G.R. Martin.
5-Hydroxytryptamine receptors. En: NC-IUPHAR subcomitee for 5-hydroxytryptamine receptors.
Br Pharmacol Soci Meeting Munich Germany, (1998), pp. 167-185
[9.]
D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Harting, G.R. Martin, E.J. Mylecharane, et al.
VII International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (serotonin).
Pharm Rev, 46 (1994), pp. 157-203
[10.]
J.J. Galligan.
Electrophysiological studies of 5-hydroxitryptamine receptors on enteric neurons.
Behav Brain Res, 73 (1996), pp. 199-201
[11.]
A. Pazos, D. Hoyer, J.M. Palacios.
The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site.
Eur J Pharmacol, 106 (1984), pp. 539-546
[12.]
B.P. Richardson, G. Engel.
The pharmacology and function of 5- HT3 receptors.
Trends Neurosci, 9 (1986), pp. 424-429
[13.]
D.W. Bonhaus, E.H.F. Wong, E. Stefanich, E.A. Kunysz, R.M. Eglen.
Pharmacological characterization of 5-hydroxytryptamine receptors in murine brain and ileum using the novel radioligand (3H)RS-42358-197: evidence for receptor heterogenity.
J Neurochem, 61 (1993), pp. 1927-1932
[14.]
J.R. Grider, J.F. Kuemmerle, J.G. Jin.
5-HT released by mucosal stimuli initiates peristaltis by activating 5-HT4/5-HT1P receptors on sensory CGRP neurons.
Am J Physiol, 270 (1996), pp. 778-782
[15.]
A.E. Foxx-Orestein, J.F. Kuemmerle, J.R. Grider.
Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine.
Gastroenterology, 111 (1996), pp. 1281-1290
[17.]
W.L. Hasler.
Serotonin receptor physiology: relation to emesis.
Dig Dis Sci, 44 (1999), pp. 108-113
[18.]
A.D. Miller.
Central mechanism of vomiting.
Dig Dis Sci, 44 (1999), pp. 39-43
[19.]
I.M. Lang.
Noxious stimulation of emesis.
Dig Dis Sci, 44 (1999), pp. 58-63
[20.]
F. Mearin, J. Flórez.
Farmacología de la motilidad digestiva y del vómito.
Terapéutica de las enfermedades del aparato digestivo. EUNUSA,, pp. 102-126
[21.]
J.S. Gida, D.C. Evansa, M.L. Cohen, D.T. Wong, D.W. Robertson, C.J. Parli.
Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
J Pharmacol Exp Ther, 273 (1995), pp. 695-701
[22.]
D.C. Currow, P.D. Noble, R.C. Stuartharris.
The clinical use of ondasetron.
Med J Aust, 162 (1995), pp. 145-149
[23.]
M.R. Tramer, D.J. Reynolds, R.A. Moore, H.J. McQuay.
Efficacy, dose-response, and safety of ondasetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Anesthesiology, 87 (1997), pp. 1271-1273
[24.]
D.C. Currow, M. Coughan, B. Fardell, N.J. Cooney.
Use of ondasetron in palliative medicine.
J Pain Symptom Manage, 13 (1997), pp. 302-307
[25.]
D.G. Tincello, M.J. Johnstone.
Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondasetron (Zofran).
Postgrad Med J, 72 (1996), pp. 688-689
[26.]
M. Tonini, S.M. Candura, E. Messori, C.A. Rizzi.
Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis.
Pharmacol Res, 31 (1995), pp. 257-260
[27.]
A. Gebauer, M. Merger, H. Killbinger.
Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn-Schmiedeberg’s Arch.
Pharmacol, 347 (1993), pp. 137-140
[28.]
F. Okada, H. Saito, N. Matsuki.
Blockade of motion and cisplatin- induced emesis by a 5-HT2 receptor agonist in Suncus murinus.
Br J Pharmacol, 114 (1995), pp. 931-934
[29.]
G. Rederich, A. Rappoport, N. Cutler, R. Hazelrigg, B. Jamerson.
Oral sumatriptan for the long-term treatment of migraine: clinical findings.
Neurology, 45 (1995), pp. 15-20
[30.]
S. Huang, J.L. Lavine.
Efficacy of sumatriptan in aborting attacks of cyclic vomiting.
Gastroenterology, 112 (1997), pp. A751
[31.]
A.J. Pascual, C. Del Arco, T. Aromon, E. Del Olmo, E. Castro, A. Pazos.
Autoradiographic distribution of (3H)-sumatriptan-binding sites in post-mortem human brain.
Cephalalgia, 16 (1996), pp. 287-288
[32.]
F. Okada, Y. Torii, H. Saito, N. Matsuki.
Antiemetic effects of serotoninergic 5-HT1A receptor agonists in Suncus murinus.
Jpn J Pharmacol, 64 (1994), pp. 109-114
[33.]
I.M. Van Vliet, H.G.M. Westenberg, J.A. Den Boer.
Effects of the 5-HT1A receptor agonist flesinoxam in the panic disorder.
Psychopharmacol, 127 (1996), pp. 174-180
[34.]
M.C. Wolf, J.D. Leander.
Comparison of the antiemetic effects of 5-HT1A agonist LY228729, and 5-HT3 antagonists in the pigeon.
Pharmacol Biochem Behav, 52 (1995), pp. 571-575
[35.]
J.R. Grider, A.E. Foxx-Orestein, J.G. Jin.
5-Hydroxytrypamine 4 receptor antagonist initiates peristaltic reflex in human, rat, and guinea pig intestine.
Gastroenterology, 115 (1998), pp. 370-380
[36.]
J.G. Jin, A.E. Foxx-Orestein, J.R. Grider.
Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5- HT3 receptors.
J Pharmacol Exp Ther, 288 (1999), pp. 93-97
[37.]
M.R. Briejer, L.M. Akkermans.
Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility.
Pharmacol Rev, 47 (1995), pp. 631-651
[39.]
H. Kilbinger, R. Kruel, I. Pfeuffer-Friederich, I. Wessler.
The effects of metoclopramide on acetylcholine release and on smooth muscle response in the isolated guinea-pig ileum. Naunyn- Scmiedeberg’s Arch.
Pharmacol, 319 (1982), pp. 231-238
[40.]
G.J. Sanger.
Effects of metoclopramide and domperidone on cholinergically mediated contractions of human isolated stomach muscle.
J Pharm Pharmacol, 37 (1985), pp. 661-664
[41.]
I. Monkovic, D. Willner, M.A. Adam, M. Brown, R.R. Crenshaw, C.E. Fuller, et al.
Substituted benzamides: potential non-dopaminergic antagonists of chemotherapy-induced nausea and emesis.
J Med Chem, 31 (1988), pp. 311-315
[42.]
A.G. Johnson.
Controlled trial of metoclopramide in the treatment of flatulent dyspepsia.
Br Med J, 2 (1971), pp. 25-26
[43.]
W.J. Snape, W.M. Battle, S.S. Schwartz, S.N. Braunstein, H.A. Goldstein, A. Alavi.
Metoclopramide to treat gastroparesis due to diabetes mellitus. A double-blind controlled trial.
Ann Intern Med, 96 (1982), pp. 444-446
[44.]
C.A. Rizzi, L. Manzo, L. Onori.
Novel enteric 5-HT4 receptors and gastrointestinal prokinetic action.
Pharmacol Res, 24 (1991), pp. 5-14
[45.]
S.S. Hedge, A.G. Wong, M.R. Perry, P. Ku, T.M. Moy, M. Loeb, et al.
5HT4 receptor mediated stimulation of gastric emptying in rats. Naunyn-Schmiedeberg’s Arch.
Pharmacol, 351 (1995), pp. 589-595
[46.]
M. Tonini, F. De Ponti, A. Di Nucci, F. Crema.
Cardiac adverse effects of gastrointestinal prokinetics.
Aliment Pharmacol Ther, 13 (1999), pp. 1585-1591
[47.]
L.R. Wiseman, D. Faulds.
Cisapride. An update review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.
Drugs, 47 (1994), pp. 116-152
[48.]
M. Tonini, R. Ciccocioppo, L. Onori.
Prokinetic drugs: a new approach to the treatment of functional disorders of the large bowel.
Riv It Colonproctol, 11 (1992), pp. 172-180
[49.]
S.A. Müller-Lissner.
Cisapride in chronic idiopathic constipation: can the colon be re-educated?.
Bavarian constipation study group. Eur J Gastroenterol Hepatol, 7 (1995), pp. 69-73
[50.]
K. Schutze, G. Brandstatter, B. Dragosics, et al.
Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome.
Aliment Pharmacol Ther, 11 (1997), pp. 387-394
[51.]
F.S. Tam, K. Hillier, K.T. Buce.
Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle.
Br J Pharmacol, 113 (1994), pp. 143-150
[52.]
R.A. Borman, D.E. Burleigh.
Evidence for the involvement of a 5- HT4 receptor in the secretory response of human small intestine to 5-HT.
Br J Pharmacol, 110 (1993), pp. 927-928
[53.]
S. Kato, I. Fujiwara, N. Yoshida.
Nitrogen-containing heteroalicycles with serotonin receptor binding affinity: development of gastroprokinetic and antiemetic agents.
Med Res Rev, 19 (1999), pp. 25-73
[54.]
M. Ruth, B. Hamelin, K. Rohss, L. Lundell.
The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophagal reflux disease.
Aliment Pharmacol Ther, 12 (1998), pp. 35-40
[55.]
N. Yoshida.
Pharmacological effects of the gastroprokinetic agent mosapride citrate.
Nippon Yakurigaku Zasshi, 113 (1999), pp. 299-307
[56.]
M.R. Briejer, P. Van Deale, J.P. Bosmans, E. Ghoos, J. Eelen, J.A. Schuurkes.
Dose-dependent effects after oral and intravenous administration of RO-93877 on colonic motility in conscious dogs.
Gastroenterology, 112 (1997), pp. A704
[57.]
A.V. Emmanuel, M.A. Kamm, A.J. Roy, K. Antonelli.
Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers.
Gut, 42 (1998), pp. 511-516
[58.]
E.P. Bouras, M. Camilleri, D.D. Burton, S. McKinzie.
Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.
Gut, 44 (1999), pp. 682-686
[59.]
C.M. Prather, M. Camilleri, A.R. Zinsmeister, S. McKinzie, G. Thomforde.
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
Gastroenterology, 118 (2000), pp. 463-468
[61.]
G.W. Gullkinson, R.F. Loeffler, M.A. Viriña.
Relationship of serotonin- 3 receptor antagonist activity to gastric emptying and motor- stimulating actions of prokinetic drugs in dogs.
J Pharmacol Exp Ther, 258 (1991), pp. 103-110
[62.]
N.J. Talley, S.F. Phillips, A. Haddad, L.J. Miller, C. Twomey, A.R. Zinsmeister, et al.
GR 38032F (ondasetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.
Dig Dis Sci, 35 (1990), pp. 477-480
[63.]
M. Delvaux, J.M. Maisin, Y. Arany, P. Atlan, M.J. Cabanis, M. Canal, et al.
Effect of the 5-HT3 antagonist/5-HT4 agonist linitopride on esophageal motility in healthy volunteers. Manometric study.
Gastroenterology, 104 (1993), pp. 496
[64.]
M.R. Von der Ohe, R.B. Hanson, M. Camilleri.
Serotonergic mediation of postpandrial colonic tonic and phasic responses.
Gut, 35 (1994), pp. 536-541
[65.]
R.J. Gralla, R.M. Navari, P.J. Hesketh, W. Popovic, et al.
Singledose oral granisetron has equivalent antiemetic efficacy to intravenous ondasetron for highly emetogenic cisplatin-based chemotherapy.
J Clin Oncology, 16 (1998), pp. 1568-1573
[66.]
M. Camilleri, E.A. Mayer, D.A. Drossman, et al.
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5HT3-receptor antagonist.
Aliment Pharmacol Ther, 13 (1999), pp. 610-620
[67.]
A.W. Mangel, A.R. Northcutt.
The safety and efficacy of alosetron, a 5HT3 receptor antagonist, in female irritable bowel syndrome patients.
Aliment Pharmacol Ther, 13 (1999), pp. 77-82
[68.]
D.G. Maxton, J. Morris, P.J. Whorwell.
Selective 5-hydroxytryptamine antagonists: a role in the irritable bowel syndrome and functional dyspepsia?.
Aliment Pharmacol Ther, 10 (1996), pp. 595-599
[69.]
L.A. Houghton, N.A. Jackson, P.J. Whorwell, et al.
5HT4 antagonism in irritable bowel syndrome (IBS): effect of SB-207266A on rectal sensitivity and small bowel transit.
Gut, 4 (1997), pp. 26
[70.]
M.B. Hansen.
Serotonin, an intestinal secretagogue, receptor subtypes and intracellular mediators.
Pharmacol Toxicol, 77 (1995), pp. 3-39
[71.]
D.R. Brown.
Studies of intestinal neurotransmitter and hormone receptors.
Methods in gastrointestinal pharmacology, pp. 1-42
[72.]
M.B. Hansen, E. Skadhauge.
Ketanserin and granisetron reduce cholera toxin-induced hypersecretion in pig jejunum.
Scand J Gastroenterol, 29 (1994), pp. 908-915
[73.]
E. Beubler, A. Schirgi-Degen.
Serotonin antagonists inhibits sennoside- induced fluid secretion and diarrhea.
Pharmacology, 47 (1993), pp. 64-69
[74.]
G.M. Jensen, M.L. Grondahl, J.E. Olsen, C.G. Nielsen, E. Skadhauge, M.B. Hansen.
Effect of ondasetron on Salmonella typhimurium- induced net fluid accumulation in pig jejunum in vivo.
Comp Biochem Physiol, 118A (1997), pp. 297-299
[75.]
H. Schwörer, H. Münke, F. Stöckmann, G. Ramadori.
Treatment of diarrhea in carcinoid syndrome with ondasetron, tropisetron, and clonidine.
Am J Gastroenterol, 90 (1995), pp. 645-648
[76.]
J.M. Kellum, M.R. Budhoo, A.K. Siriwardena, E.P. Smith, S.A. Jebraili.
Serotonin induces Cl- secretion in human jejunal mucosa in vitro via nonneuronal pathway at a 5-HT(4) receptor.
Am J Physiol, 267 (1994), pp. 357-363
[77.]
Farthing MJG.
New drugs in the management of the irritable bowel syndrome.
Drugs, 56 (1998), pp. 11-21
[78.]
A.A. Alhaider, S.Z. Lei, G.I. Wilcox.
Spinal 5-HT3 receptors-mediated antinocicepcion: possible release of GABA.
J Neurosci, 11 (1991), pp. 1881-1888
[79.]
Farthing MJG.
Irritable bowel, irritable body, irritable brain?.
BMJ, 310 (1995), pp. 171-175
[80.]
M. Camilleri.
Therapeutic approach to the patient with irritable bowel syndrome.
Am J Med, 107 (1999), pp. 27-32
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
